ASH 2023 | Updated results of the BRUIN trial: pirtobrutinib in R/R MCL
Jonathon Cohen, MD, MS, Emory University School of Medicine, Atlanta, GA, comments on the updated results of the Phase I/II BRUIN trial (NCT03740529) of pirtobrutinib in relapsed/refractory (R/R) B-cell malignancies, with a focus on R/R mantle cell lymphoma (MCL). In line with previous findings, pirtobrutinib exhibited encouraging efficacy and safety in patients, including those previously treated with covalent BTK inhibitors and those with high-risk disease features. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So, at the 2023 ASH Annual Meeting, I had the opportunity to present updated results from the Phase I/II BRUIN study, specifically for the cohort of patients with relapsed/refractory mantle cell lymphoma. What we see is that, with additional follow-up, we’re continuing to have a response rate of about 49% in patients in whom the overwhelming majority have previously received covalent BTK inhibitors, and this was historically a very high-risk patient population...
So, at the 2023 ASH Annual Meeting, I had the opportunity to present updated results from the Phase I/II BRUIN study, specifically for the cohort of patients with relapsed/refractory mantle cell lymphoma. What we see is that, with additional follow-up, we’re continuing to have a response rate of about 49% in patients in whom the overwhelming majority have previously received covalent BTK inhibitors, and this was historically a very high-risk patient population. In addition, we see that the duration of that response is still around 21 months, again suggesting that for those patients that do respond, they can expect to have a very durable remission. Finally, we see that there continues to be a good safety profile. This is a well-tolerated therapy, and fortunately, we’re not seeing any unexpected or severe toxicities.
Read more...
Disclosures
Research Funding: BMS/Celgene, Novartis, Genentech, BioInvent, Lam Therapeutics, Takeda, AstraZeneca, Loxo/Lilly
Consultancy: ADCT, AstraZeneca, Abbvie, Janssen, BeiGene, Loxo/Lilly
